The study of a large set of treatment-related NEPCs showed AURKA amplification in 65% of primary prostate cancers and 86% of metastases and concurrent MYCN amplification was detected in 69% of treated prostate cancers and 83% of metastases [681]. This evidence concerns the gene AURKA and prostate carcinoma.